Company Information

CIN
Status
Date of Incorporation
08 February 2005
State / ROC
Chennai / ROC Chennai
Last Balance Sheet
31 March 2011
Last Annual Meeting
30 June 2011
Paid Up Capital
148,766,000
Authorised Capital
250,000,000

Directors

Suranjan Upadhyay
Suranjan Upadhyay
Director/Designated Partner
about 2 years ago
Deepak Calian Vaidya
Deepak Calian Vaidya
Director/Designated Partner
over 2 years ago
Venkatasubramanian Ramasubramanian
Venkatasubramanian Ramasubramanian
Director
over 18 years ago
Canakapalli Bhaktavatasala Rao
Canakapalli Bhaktavatasala Rao
Director
almost 21 years ago

Past Directors

Gopalan Balasubramanian
Gopalan Balasubramanian
Additional Director
over 17 years ago
Ranganathaiyer Narayanan
Ranganathaiyer Narayanan
Director
almost 20 years ago
Bishwajit Nag
Bishwajit Nag
Director
about 20 years ago
Kailasam Raghavendra Rao
Kailasam Raghavendra Rao
Director
almost 21 years ago

Patents

Novel Heterocycles

Described are novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are useful in the treatment of immunolo...

Cyclic Compounds As Dipeptidyl Peptidase Iv Inhibitors

Described are novel compounds of the formula (I), their derivatives, analogs,tautomeric  forms,regioisomers,stereoisomers,polymorphs,  solvates,intermediates,pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds are effective in lowering blood glucose,serum...

Heterocyclic Compounds As Phosphodiesterase Inhibitors

Described are compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) i...

Pyrimidine Compounds

Novel heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof are described. These compounds are useful in the treatment of immunolo...

Novel Hydroxamates

Provided herein are novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof which are hydroxamic acid derivatives of statins such as Atorva...

Novel Pyrimidinedione Derivatives

The present invention relates to novel pyrimidinedione derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containi...

Novel Diaryl Pyrimidinone Derivatives

The present invention relates to novel diaryl pyrimidinone derivatives of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions cont...

Novel Pyridyl Carboxamides

Novel pyridyl carboxamides of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, prodrugs and preparation thereof which can be used for the treatment of proliferative diseas...

Hdac Inhibitors

Novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof are described. These novel compounds can inhibit HDAC's and are useful as a therapeutic or ameliorating...

Oxazolidinone Derivatives

The present invention relates to novel compounds of the general formula (I), their stereoisomers, their derivatives, their pharmaceutically acceptable, salts and compositions. The present invention more particularly provides novel Oxazolidinone derivatives of the general formula (I).

Diphenyl Ether Compounds For The Treatment Of Liver Lung Disorders, Diabetic Complications And Cardiovascular Diseases

Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and no...

Novel Bridged Cyclic Compounds As Histone Deacetylase Inhibitors

Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as t...

Pyrimidine Compounds

Provided herein are heterocyclic compounds of the general formula (I), th~ir derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3 R4 and R5 are as described herein: Further descr...

Novel Compounds And Their Use

Abstract The present invention provides novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof The present invention more particularly provides novel ...

Heterocyclic Compounds As Hdac Inhibitors

The present invention relates to heterocyclic compounds of the general formula (I) their derivatives, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, prodrugs, pharmaceutically acceptable salts and compositions thereof. Also included is method for treatment...

Compounds And Their Use

Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as β-lactamase inhibitors, wh...

Hdac Inhibitors For The Treatment Of Fungal Infections

Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. The invention relates to compositions and methods to treat fungal ...

Histone Deacetylase Inhibitors

Provided herein are isoform selective histone deacetylase inhibitors of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds are isoform selective inhibitors of ...

"Novel Pyrimidone Derivatives"

AbstractThe present invention relates to novel pyrimidones of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their hydrates, their solvates, their pharmaceutically acceptable salts and pharmaceutical ly acceptable compositions c...

Novel Condensed Pyrimidones

The present invention relates to novel condensed pyrimidones of the general formula (I) their analogs, their solvates, their pharmaceutically acceptable salts and pharamaceutically acceptable compositions containing them, The present invention more particulary provides novel condensed pyrimidone derivatives ...

Documents

Form 21-290312.PDF
Copy of the Court-Company Law Board Order-290312.PDF
Copy of Board Resolution-270112.PDF
Scheme of Arrangement- Amalgamation-270112.PDF
XBRL document in respect of balance sheet 01-12-2011 for the financial year ending on 31-03-2011.pdf.PDF
XBRL document in respect of profit and loss account 01-12-2011 for the financial year ending on 31-03-2011.pdf.PDF
Form 23ACA XBRL-021211-011211 for the FY ending on-310311.OCT
Form 23AC XBRL-021211-011211 for the FY ending on-310311.OCT
Form 23B for period 010411 to 310312-270811.OCT
FormSchV-200911 for the FY ending on-310311-Revised-1.OCT
FormSchV-200911 for the FY ending on-310311.OCT
Form 32-300711.OCT
Optional Attachment 1-300711.PDF
Form 23-290711.PDF
Copy of resolution-290711.PDF
Optional Attachment 2-290711.PDF
Optional Attachment 1-290711.PDF
Form 23-250711.PDF
Copy of resolution-250711.PDF
Optional Attachment 1-250711.PDF
Optional Attachment 2-250711.PDF
Evidence of cessation-310111.PDF
Optional Attachment 1-310111.PDF
Form 32-310111-210111.PDF
Evidence of cessation-041210.PDF
Form 32-041210-281010.PDF
Form 23B-211010.OCT
FormSchV-141010 for the FY ending on-310310.OCT
Frm23ACA-210910 for the FY ending on-310310.OCT
Form23AC-210910 for the FY ending on-310310.OCT